Navigation Links
Exelixis Announces Senior Management Promotions
Date:1/4/2008

-Pamela A. Simonton Promoted to Executive Vice President and General

Counsel- -Gisela M. Schwab Promoted to Executive Vice President and Chief Medical

Officer-

SOUTH SAN FRANCISCO, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced promotions for two members of its senior management team. Pamela A. Simonton, Senior Vice President of Patents and Licensing, has been promoted to Executive Vice President and General Counsel and Dr. Gisela M. Schwab, Senior Vice President and Chief Medical Officer, has been promoted to Executive Vice President and Chief Medical Officer.

"I am happy to promote both Pamela and Gisela. Both have played key roles in Exelixis' accomplishments, and both promotions are well-deserved. Pamela will now have responsibility for all corporate legal matters and legal services in support of Exelixis' business and corporate objectives," said George Scangos, Ph.D., President and Chief Executive Officer of Exelixis. "Pamela has been responsible for all of the patent and licensing activity since her arrival in 2000 and has played a major role in our partnering activities as well. Dr. Schwab will continue to lead the Development Organization as we plan to move 3 compounds into pivotal trials in the first half of 2008."

Ms. Simonton has served as Senior Vice President, Patents and Licensing, since January 2004. Previously, she served as Vice President of Corporate Technology Development from April 2000 through December 2003. From July 1996 to April 2000, she served as Vice President, Licensing and Acquisitions for Bayer Corporation's Pharmaceutical Division. From September 1994 to July 1996, Ms. Simont
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
2. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
3. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
4. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
6. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
9. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
10. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
11. Exelixis Announces Closing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
(Date:12/11/2009)... December 11, 2009 -- Esco announces the opening of a NEW ... as a technical service, training and logistics center to support Esco,s ... New Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... opening of a NEW 2nd North American facility in Marietta, OH. ...
(Date:12/10/2009)... Institute (NEI), a division of the National Institutes of Health ... help fund its development of a non-invasive, passive diffusion-based treatment ... ... Salt Lake City, UT (PRWEB) December 10, 2009 ... National Institutes of Health (NIH), awarded a $2.18 million grant ...
(Date:12/10/2009)... of advanced flow measurement, control, and level solutions, ... as Global Level Product Manager effective November 30, ... enhance market penetration of the level measurement products ... from Lafarge Corp, a manufacturer of building materials, ... Sales. Bayda will report to Brooks Instrument Vice ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3
... (Nasdaq:,CPHD) today announced the appointment of leading ... Fred Tenover, Ph.D., as,Senior Director of Scientific ... liaison,with the Infection Control community and will ... "The objective of the Cepheid HAI ...
... 9 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) ... 25mg meclizine HCl tablets immediately. At,this time, Par believes ... Par marketed meclizine prior to an explosion at ... has since qualified a new API source and,received the ...
... YARDLEY, Pa. and WOBURN, Mass., July 9 ... Business, Technology and,Regulatory strategies, and CBI Research Inc., ... executives in the pharmaceutical,and biotech industries, today announced ... will chair CBI,s "3rd Annual Manufacturing Execution,Systems for ...
Other Biology Technology:Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3Par Pharmaceutical to Launch meclizine HCL Tablets 2Axendia's President to Chair 3rd Annual MES for Life Sciences Congress 2
(Date:12/14/2009)... researchers from the Astrobiology Centre (INTA-CSIC) has shown that ... the formation of the most basic biological molecules can ... to carry out this study, published in the journal ... chemical conditions of the early Earth. , "We have ... solutions it produces hydrogen cyanide, a substance that could ...
(Date:12/14/2009)... WAYNE, Pa., Dec. 14 MODA Technology ... monitoring (EM), utility and product testing for the ... MODA 3.0, the company,s third generation mobile data ... (QC) organizations to further automate their regulated manufacturing ... new capabilities: ,, Fully-Configurable Test Methods: ...
(Date:12/13/2009)... Scientists have resolved a question about how a ... works using biosensors that reveal previously hidden components ... Although delusions and hallucinations characterize the illness, people ... recall information in a particular order, difficulties that ... or function well, said Lee Schroeder, a student ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 1Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 2Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 3Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 4Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 5Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 1Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 3Neogen Acquires Gen Probes BioKits Food Safety Business 6639 1Neogen Acquires Gen Probes BioKits Food Safety Business 6639 2
... stand-in for humans in medical research, thanks to genomes ... behave differently in mouse and man, a study by ... Zhang reveals. , Their results, which have implications for ... appear in the current issue of the journal Proceedings ...
... Studying thousands of patients, Japanese researchers have found ... of three cancers esophageal, head and neck, and ... risk of developing these diseases. , In the May ... of the American Association for Cancer Research, scientists from ...
... bioMETRX, Inc. (OTC,Bulletin Board: BMRX) a leading developer ... has filed 5 new patent applications with,the United ... covered by the filings include tool storage chests, ... The,traditional products that are the subject of the ...
Other Biology News:Mouse can do without man's most treasured genes 2Mouse can do without man's most treasured genes 3Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2bioMETRX, Inc. Files for Several New Patents 2